Investor Relations

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based upon a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance’s initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis, and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.

NASDAQ | RVNC
19.65
- 0.65 (-3.20%)
11:51 AM ET on Jan 24, 2017
Delayed at least 20 minutes.

INVESTOR RELATIONS CONTACTS
Jeanie D. Herbert
Sr. Director, Investor Relations
714-325-3584
jherbert@revance.com


Burns McClellan
Ami Bavishi
212-213-0006
abavishi@burnsmc.com

Revance Therapeutics, Inc.
P.O. Box 303
Newark, California 94560-0303
Phone: (510) 742-3400
Fax: (510) 742-3401

Transfer Agent
Computershare
P.O. Box 30170
College Station, TX, 77842
USA
+1 (877) 373 6374
(US, Canada, Puerto Rico)
+1 (781) 575 3120 (non-US)
web.queries@computershare.com

Press Releases

Events & Webcasts

Presentations and Corporate Materials

Investor Relations
Date Document Type
Jan 8, 2017 Investor Presentation
Jan 8, 2017 Fact Sheet
Dec 12, 2016 Phase 2 Cervical Dystonia Interim Results Presentation
= add file to Briefcase
Shareholder Tools